Efeito do tipo antidepressivo da benzamida N-(3-(fenilselenil)prop-2-in-1-ílica em camundongos: envolvimento do sistema serotoninérgico

Abstract

Depression is a disabling mental illness characterized by psychological and behavioral changes. Changes in monoaminergic neurotransmitter levels, such as dopamine, serotonin and norepinephrine, are closely associated with the pathogenesis of depression. Selenium organic compounds have several pharmacological properties, among them the antidepressant effect. In this context, this study evaluated the antidepressant-like effect of N-(3-(phenylselanyl)prop-2-yn-1- yl)benzamide (SePB), an organoselenium compound containing the benzamide moiety, on the forced swim test (FST) and the tail suspension test (TST) in mice, as well as the involvement of the serotonergic system in anti-immobility effects. SePB, in time (15-120 min) and dose-response (1-50 mg/kg, intragastric) curves, reduced the animal immobility during FST and TST, without changing the locomotor activity in the open-field test (OFT), which demonstrate its antidepressant-like effect. The dose of 10 mg/kg of SePB and the pre-treatment time of 30 minutes were selected to test the involvement of the serononergic system in the antidepressant-like effect of this compound. The preadministration of the serotonin (5-HT) depletor p chlorophenylalanine (pCPA; 100 mg/kg, intraperitoneal route, once daily for 4 days) prevented the anti-immobility effect of SePB, indicating that the serotonergic system is involved in the SePB antidepressant-like effect. In addition, the preadministration of the selective serotonergic receptor antagonists WAY100635 (0.1 mg/kg, subcutaneous route, a selective 5-HT1A receptor antagonist), ketanserin (1 mg/kg, i.p., a 5-HT2A/2C receptor antagonist) and ondansetron (1 mg/kg, i.p., a selective 5-HT3 receptor antagonist) also prevented the anti-immobility effect of SePB, demonstrating that these receptors are involved in the antidepressant-like effect of SePB. This study demonstrated an effect of SePB antidepressant type, whose mechanism of action is related to the modulation of the serotonergic system.